Business Standard

Monday, December 23, 2024 | 01:00 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Pfizer buys AstraZeneca's Neksium antacid

Gelusil and Mucaine are two other drugs in the antacid space the company has

Photo courtesy: Reuters
Premium

Photo courtesy: Reuters

Veena Mani New Delhi
Pharmaceutical major Pfizer India has signed an agreement with AstraZeneca’s Swedish arm to acquire the latter’s drug, Neksium, for Rs 75 crore. 

Neksium was launched in India in 2006 and had developed strong equity with doctors, as a leading, high-quality product in the anti-peptic ulcerant space. 

“The Neksium acquisition is aligned with our stated ambition of portfolio expansion through organic and inorganic growth in our focus therapy areas. With this acquisition, we will accelerate our growth and strengthen our leadership position in the gastrointestinal therapy area.” said S Sridhar, managing director, Pfizer.

This is the second deal Pfizer and AstraZeneca have got into

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in